All of the information contained within this website has been compiled from sources believed to be reliable, but no warranty, expressed or implied, is given that the information is complete or accurate or that it is fit for a particular purpose. All such warranties are expressly disclaimed and excluded. Any opinions, recommendations and forecasts referred to are not those of Walbrook PR Limited but are expressly those of third parties, such as investment analysts and financial journalists. Such opinions, recommendations and forecasts may have been superseded and thus may not necessarily be the current opinions, recommendations and forecasts of the relevant analyst/broker. None of the content of this website should be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell, the securities of any listed Company mentioned or featured herein as it is for information only. Any recommendations referred to by third parties do not necessarily imply the suitability of particular securities for individual situations. The value of securities and the income from them may fluctuate. It should be remembered that past performance is not necessarily a guide to future performance. You are strongly advised to seek guidance from a professional investment adviser before entering into any contract to buy or sell any security featured herein. By reading this disclaimer, and ticking the box below, you confirm that you accept and understand its content, and that you shall not hold Walbrook PR Limited, its directors and staff nor any of its subsidiaries or connected companies liable for any loss that you may sustain should you decide to buy or sell any of the mentioned securities.
Hemogenyx Pharmaceuticals plc
Pharmaceuticals and Biotechnology (Biotechnology)
US based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation.
Not all Walbrook clients have a handy 2 page summary available. Click on "Register your interest" and we'll let the Company know that you think this would be useful
Investor Access Events
I'm sorry that there is no Investor Access event planned at the moment - click on "Register your Interest" and we'll tell the Company that you'd like to attend one in the future and update you when an event is planned.